Kenneth I. Ataga - Concepedia

Author

Kenneth I. Ataga

University of North Carolina at Chapel Hill ORCID

Also Known As

ATAGA K., Alvarez, Ofelia A., Amin, Chirag, Archer, David R., Ataga, Kenneth I., Caughey, Melissa, De Castro, Laura M., Deal, Allison M., Delaney, John, Derebail, Vimal K.

302

Publications

10.2K

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill University of Tennessee Health Science Center Augusta University University of Illinois Chicago Emory University

About

Kenneth I. Ataga is an author at University of North Carolina at Chapel Hill specializing in medicine, hematology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	1.6K
2	Public Health	6	6	300
3	Health Sciences	4	4	920
4	Allergy	3	3	222
5	Social Sciences	1	1	28

Kenneth I. Ataga

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia Martin H. Steinberg, Franca B. Barton, Oswaldo Castro, JAMA	2003	889
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter, New England Journal of Medicine	2016	837
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease Elliott Vichinsky, Carolyn Hoppe, Kenneth I. Ataga, New England Journal of Medicine	2019	581
The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up Martin H. Steinberg, William F. McCarthy, Oswaldo Castro, American Journal of Hematology Drug SafetyHematologyClinical TrialsSickle Cell AnemiaToxicology	2010	473
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study Kenneth I. Ataga, Charity G. Moore, Susan Jones, British Journal of Haematology	2006	293
Factors associated with survival in a contemporary adult sickle cell disease cohort Hany Elmariah, Melanie E. Garrett, Laura M. De Castro, American Journal of Hematology ImmunohematologySickle Cell DiseaseDisease ProgressionPediatric HematologyLongevity	2014	286
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease Elizabeth S. Klings, Roberto F. Machado, Robyn J. Barst, American Journal of Respiratory and Critical Care Medicine	2014	248
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia Kenneth I. Ataga, Wally R. Smith, Laura M. De Castro, Blood	2008	223
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) Kenneth I. Ataga, Marvin Reid, Samir K. Ballas, British Journal of Haematology	2011	214
Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease Eugene P. Orringer, James F. Casella, Kenneth I. Ataga, JAMA	2001	194

Page 1